APA   Click to copy
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019). Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. The Lancet Haematology, 6, e20–e28.

Chicago/Turabian   Click to copy
Dawwas, Ghadeer K, Joshua Brown, Eric Dietrich, and Haesuk Park. “Effectiveness and Safety of Apixaban versus Rivaroxaban for Prevention of Recurrent Venous Thromboembolism and Adverse Bleeding Events in Patients with Venous Thromboembolism: a Retrospective Population-Based Cohort Analysis.” The Lancet Haematology 6 (2019): e20–e28.

MLA   Click to copy
Dawwas, Ghadeer K., et al. “Effectiveness and Safety of Apixaban versus Rivaroxaban for Prevention of Recurrent Venous Thromboembolism and Adverse Bleeding Events in Patients with Venous Thromboembolism: a Retrospective Population-Based Cohort Analysis.” The Lancet Haematology, vol. 6, Elsevier, 2019, pp. e20–e28.

@article{dawwas2019a,
  title = {Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis},
  year = {2019},
  journal = {The Lancet Haematology},
  pages = {e20--e28},
  publisher = {Elsevier},
  volume = {6},
  author = {Dawwas, Ghadeer K and Brown, Joshua and Dietrich, Eric and Park, Haesuk}
}